Efficiency and Side Effects of Sorafenib Therapy for Advanced Hepatocellular Carcinoma: A Retrospective Study by the Anatolian Society of Medical Oncology |
Berk, Veli
(Department of Medical Oncology, Erciyes University Faculty of Medicine)
Kaplan, Mehmet Ali (Department of Medical Oncology, Dicle University Faculty of Medicine) Tonyali, Onder (Department of Medical Oncology, Gazi University Faculty of Medicine) Buyukberber, Suleyman (Department of Medical Oncology, Gazi University Faculty of Medicine) Balakan, Ozan (Department of Medical Oncology, Gaziantep University Faculty of Medicine) Ozkan, Metin (Department of Medical Oncology, Erciyes University Faculty of Medicine) Demirci, Umut (Department of Medical Oncology, Ataturk Research and Training Hospital) Ozturk, Turkan (Department of Medical Oncology, Karadeniz Technical University Faculty of Medicine) Bilici, Ahmet (Department of Medical Oncology, Sisli Etfal Research and Training Hospital) Tastekin, Didem (Department of Medical Oncology, Necmettin Erbakan University Meram Faculty of Medicine) Ozdemir, Nuriye (Department of Medical Oncology, Ankara Numune Research and Training Hospital) Unal, Olcun Umit (Department of Medical Oncology, Dokuz Eylul University Faculty of Medicine) Oflazoglu, Utku (Department of Medical Oncology, Dokuz Eylul University Faculty of Medicine) Turkmen, Esma (Department of Medical Oncology, Trakya University Faculty of Medicine) Erdogan, Bulent (Department of Medical Oncology, Trakya University Faculty of Medicine) Uyeturk, Ummugul (Department of Medical Oncology, Ankara Oncology Research and Training Hospital) Oksuzoglu, Berna (Department of Medical Oncology, Ankara Oncology Research and Training Hospital) Cinkir, Havva Yesil (Department of Medical Oncology, Ankara Oncology Research and Training Hospital) Yasar, Nurgul (Department of Medical Oncology, Kartal Research and Training Hospital) Gumus, Mahmut (Department of Medical Oncology, Kartal Research and Training Hospital) |
1 | Bai W, Wang YJ, Zhao Y, et al (2013). Sorafenib in combination with transarterial chemoembolization improves the survival of patients with unresectable hepatocellular carcinoma: a propensity score matching study. J Dig Dis, 14, 181-90. DOI ScienceOn |
2 | Brunocilla PR, Brunello F, Carucci P, et al (2013). Sorafenib in hepatocellular carcinoma: prospective study on adverse events, quality of life, and related feasibility under daily conditions. Med Oncol, 30, 345. DOI |
3 | Chang MH, Chen CJ, Lai MS, et al (1997). Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. N Engl J Med, 336, 1855-9. DOI ScienceOn |
4 | Cheng AL, Kang YK, Chen Z, et al (2009). Efficacy and safety of sorafenib in patients in the asia-pacific region with advanced hepatocellular carcinoma: a phase III randomised,doubleblind, placebo-controlled trial. Lancet Oncol, 10, 25-34. DOI ScienceOn |
5 | Eisenhauer EA, Therasse P, Bogaerts J, et al (2009). New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer, 45, 228-47. DOI ScienceOn |
6 | European Association for Study of Liver; European Organisation for Research and Treatment of Cancer (2012). EASLEORTC clinical practice guidelines: management of hepatocellular carcinoma. Eur J Cancer, 48, 599-641. DOI ScienceOn |
7 | Ezzoukhry Z, Louandre C, Trecherel E, et al (2012). EGFR activation is a potential determinant of primary resistance of hepatocellular carcinoma cells to sorafenib. Int J Cancer, 131, 2961-9. DOI ScienceOn |
8 | Huynh H, Nguyen TT, Chow KH, et al (2003). Over-expression of the mitogen-activated protein kinase (MAPK) kinase (MEK)-MAPK in hepatocellular carcinoma: its role in tumor progression and apoptosis. BMC Gastroenterol, 3, 19. DOI ScienceOn |
9 | Kostner AH, Sorensen M, Olesen RK, et al (2013). Sorafenib in advanced hepatocellular carcinoma: a nationwide retrospective study of efficacy and tolerability. ScientificWorld Journal, 2013, 931972. |
10 | Llovet JM, Ricci S, Mazzaferro V, et al (2008); Sharp investigators study group. sorafenib in advanced hepatocellular carcinoma. N Engl J Med, 359, 378-90. DOI ScienceOn |
11 | Oliveri RS, Wetterslev J, Gluud C (2011). Transarterial(chemo) embolisation for unresectable hepatocellular carcinoma. Cochrane Database Syst Rev, 16, 4787. |
12 | Schmitt M, Horbach A, Kubitz R, et al (2004). Disruption of hepatocellular tight junctions by vascular endothelial growth factor (VEGF): a novel mechanism for tumor invasion. J Hepatol, 41, 274-83 DOI ScienceOn |
13 | Siegel R, Naishadham D, Jemal A (2012). Cancer statistics, 2012. CA Cancer J Clin, 62, 10-29. DOI ScienceOn |
14 | Stock P, Monga D, Tan X, et al (2007). Platelet-derived growth factor receptor-alpha: a novel therapeutic target in human hepatocellular cancer. Mol Cancer Ther, 6, 1932-41. |
15 | Zhu AX, Rosmorduc O., Evans J, et al (2012). A phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with hepatocellular carcinoma (HCC). 37th ESMO Congress; Vienna, Austria. European Society Med Oncol. |